Spelling suggestions: "subject:"HDAC inhibitors"" "subject:"HDAC 2inhibitors""
21 |
Nanosondes épigénétiques / Epigenetic nanoprobesBahhaj, Fatima El 30 October 2014 (has links)
Les cibles épigénétiques telles que les histones désacétylases (HDAC) sont étudiées comme nouveaux traitements anticancéreux, leur fonctionnement anormal étant associée aux processus cancéreux. De nombreux inhibiteurs de ces enzymes sont apparus tel que le SAHA ou le CI-994. Notre laboratoire a développé un nouvel analogue de la trichostatine A appelé NODH. Malgré leur activité anticancéreuse in vitro prometteuse, ces inhibiteurs souffrent de leur manque de solubilité, d'effets toxiques et de leur rapide métabolisation par l'organisme. Afin de pallier ces limitations, ces iHDAC peuvent être conjugués à des vecteurs capables de les transporter dans l'organisme et de les libérer une fois la cible tumorale atteinte. Ce travail de thèse a consisté dans un premier temps à développer des prodrogues acido-sensibles capable de libérer la substance active après endocytose par les cellules. Ces systèmes ont été appliqués aux trois iHDAC SAHA, CI-994 et NODH. Les prodrogues développées ont ensuite été accrochées sur des nanoparticules polymériques connues pour leur biocompatibilité et leur accumulation dans les tumeurs grâce à l'effet EPR. L'activité anticancéreuse de certaines nanoparticules a été validée par des tests in vitro et in vivo. Un deuxième travail a été entrepris concernant la préparation de prodrogues fluorescentes pH labiles capables de libérer la substance active et de moduler la fluorescence par la variation du pH. La dernière partie de ce travail a été consacrée à la mise au point d'une nouvelle méthode de synthèse par voie superacide potentiellement stéréosélective de benzofuranones nécessaires à la préparation d'analogues de NODH. / Epigenetic targets like histone deacetylases (HDAC) are studied as new anticancer treatments, their dysfunctioning being associated to cancer mechanisms. Several epigenetic target inhibitors have been developed like SAHA or CI-994. Our group has developed a new trichostatin A analogue called NODH. Despite their promising in vitro anticancer effect, these inhibitors suffer from lack of solubility, toxic effects and rapid clearance. These constrains make the HDACi good candidates for ligation to vectors able to carry them in the body and to release them when the tumor is reached. The first part of this thesis work has focused on the development of acid sensitive prodrugs able to release an active substance after cellular internalization by endocytosis. These systems were applied to three HDACi SAHA, CI-994 and NODH. These prodrugs were then conjugated to polymeric nanoparticles known for their biocompatibility and their accumulation in tumors exploiting the EPR effect. The anticancer activity of some nanoparticles has been validated by in vitro and in vivo tests. The second part of this work was carried out in order to prepare pH sensitive fluorescent prodrugs able to release the active molecule and to modulate the fluorescent effect by pH changes. The last part of this work was dedicated for the development of a new synthesis in suparacid potentially stereoselective of several benzofuranones required for the preparation of NODH analogs.
|
22 |
Conception, synthèse et vectorisation de molécules apparentées à l'isocombrétastatine A-4 : Exploration de nouvelles réactivites des composés diazo-précurseurs / Design, synthesis and vectorization of isocombretastatin A-4 analogues : Exploration of new reactivities of diazo-precursor compoundsLamaa, Diana 15 November 2019 (has links)
Les travaux de thèse concernent la synthèse et la vectorisation d'analogues de la combrétastatine A-4, une molécule naturelle connue pour ses propriétés anti-vasculaires et cytotoxiques. Ces recherches se situent à l’interface de la chimie et de la biologie.D'une part, des études en méthodologie de synthèse, mettant en œuvre des réactions de couplages entre des composés diazo-précurseurs et des halogénoarènes ou des amines ont été réalisées dans le but de fournir des outils de synthèse nécessaires à la constitution de chimiothèques. Ces études ont conduit à la synthèse des 2-pyridilalkylamines à partir de pyridotriazole et d’amines, à la synthèse du motif 1,1-diaryléthyl via une réaction green ainsi qu'à l’accès au noyau benzofurane à travers une réaction « one-pot ».D’autre part, des analogues duaux de l'isocombrétastatine A-4, inhibiteurs de la tubuline et des histones désacétylases ont été développés. L'évaluation biologique de ces analogues a permis d’identifier deux molécules « lead » dont les activités antiprolifératives sur des lignées cellulaires cancéreuses sont de l'ordre du nanomolaire. D'excellents résultats d'inhibition de la polymérisation de la tubuline et de l’histone déacétylase 8 ont également été observés.Finalement, des essais de vectorisation de quelques analogues de l’isoCA-4 sous forme de liposomes ou d’ADC ont été réalisés. / The thesis reports the synthesis and vectorization of combretastatin A-4 analogues, a natural molecule known for its anti-vascular and cytotoxic properties. Our research work is at the chemistry-biology interface.On the first hand, synthetic methodology studies were performed, indeed coupling reactions between diazo-precursors and haloarenes or amines have been carried out providing new and interesting synthethic tools. These studies led to the synthesis of 2-pyridylalkylamines from pyridotriazole and amines, as well as to the synthesis of the 1,1-diarylethylene compounfs via a green reaction and finally to access to the benzofuran ring through a one-pot fashion reaction ".On the other hand, dual targeting analogs of isocombretastatin A-4 with tubulin and histone deacetylases inhibition properties have been developed. The biological evaluation of these analogs allowed us to identify two lead molecules whose antiproliferative activities on cancer cell lines are in the order of nanomolar. These molecules showed an excellent tubulin polymerization and histone deacetylase 8 inhibitions.Finally, vectorization assays of some isoCA-4 analogs using liposomes or ADCs were performed.
|
23 |
Spinal Muscular Atrophy: Evidence of a Multi-System DiseaseDeguise, Marc-Olivier 10 January 2020 (has links)
Spinal muscular atrophy (SMA) is a devastating recessive neurological disorder thought to be affecting primarily the motor neurons. As such, paralysis, motor weakness and death ensue. While SMA is most commonly seen in infants and children, it can span all ages. Its genetic etiology revolves around the homozygous deletion or mutation of the SMN1 gene, whose product (SMN protein) has critical and ubiquitous roles in mRNA splicing, amongst various other functions in mRNA metabolism. As such, SMN depletion in other non-neuronal cells type is likely to have physiological repercussions, and perhaps modulate the SMA phenotype. Herein, we identify the molecular pathways of atrophy in skeletal and cardiac muscle of two mouse models of SMA and their therapeutic modulation via the histone deacetylase inhibitor trichostatin A. We also identify dramatic changes in immune organs in mouse models of SMA, which could impact susceptibility to infections. Furthermore, we establish the presence of important defects in fatty acid homeostasis in the liver and plasma seen in both mouse models and SMA patients. Finally, we provide the first mild mouse model of SMA that reliably reproduces canonical features of SMA, permitting aging studies. This model presents with a prominent myopathic phenotype prior to motor neuron death, without extra-neuronal involvement during the course of its lifespan. Overall, our work shows multiple potentially clinically relevant defects in extra-neuronal organs, provides ways to abrogate them and provides a framework to study them over the course of aging.
|
24 |
Novel proapoptotic p63 isoforms are driven by an endogenous retrovirus in the male germ line of humans and great apes, likely increasing genome stability / Neue proapoptotische p63-Isoformen werden von einem endogenen Retrovirus in den männlichen Keimbahnen von Mensch und Menschenaffen gesteuert und erhöhen wahrscheinlich die genomische StabilitätBeyer, Ulrike 29 October 2010 (has links)
No description available.
|
25 |
Mechanisms Controlling Luminal Identity of Breast TumoursIsmail, Houssam 12 1900 (has links)
No description available.
|
26 |
Regulation and Characterization of Transcription Factor Activator Protein-2 Alpha (AP-2α)Nama, Srikanth January 2009 (has links) (PDF)
Introduction
AP2α is a 52 kDa retinoic acid inducible and developmentally regulated activator of
transcription, which binds to the DNA in a sequence-specific manner. Transcription factor AP-2α was isolated from HeLa cells by affinity chromatography using specific binding sites with in SV40 and human metallothionein promoters. Further screening of HeLa cDNA library with oligonucleotide probes predicted partial peptide sequence which led to the isolation of AP-2α
cDNA and subsequently it was mapped to chromosome 6 near HLA locus. A differentially spliced version of AP-2α, which lacks most of the C-terminus, encodes a dominant negative protein (AP-2B). Subsequent studies led to the identification of four more isoforms: AP-2β, AP-2γ, AP-2δ and AP-2ε. AP-2 family members can form homo or hetero dimers among themselves through the unique C-terminal helix span helix motif and bind DNA through basic domain lies N-terminus of DNA binding domain.
Several evidences suggest that AP-2α can act as a tumor suppressor gene. It has been
shown that AP-2α can activate growth suppressor genes like p21WAF1/CIP1. Transforming viral oncogenes like adenovirus E1A and SV40 large T antigen have been shown to alter AP-2α function. In addition, reduced expression of AP-2α has been reported in human breast, ovary,
colon, skin, brain and prostate cancers. Further, supporting evidences suggest that more invasiveness and tumorogenicity was observed when dominant negative mutant of AP-2α was expressed in melanoma cells.
In this work, we have carried out a systematic study to find the various signal
transduction pathways which regulate AP-2 activity as well as we attempted to demonstrate the importance of DNA binding domain in the growth inhibitory functions of AP-2α. HDAC inhibitors (HDIs) activate AP-2 activity through spleen tyrosine kinase (Syk)
In the literature, ample evidences are available that genotoxic drugs such as adriamycin, induce tumor suppressors like p53 and p73. In this study, we have screened pharmacological drugs which damage DNA and specific inhibitors of various signal transduction pathways for their ability to activate AP-2 activity. AP-2 specific reporter, 3Χ-AP2-CAT was used in this
study to measure the AP-2 activity. Of all the compounds studied, we found that Histone
Deacetylase Inhibitors (HDIs) efficiently activated AP-2 activity and was found to be specific as they failed to activate 3X-AP2 mut CAT, which contains mutated AP-2 binding sites as well as pGL tk Luc, which contains thymidine kinase minimal promoter and no AP-2 binding sites.
To understand the mechanism of HDI-mediated of AP-2 activation, AP-2 isoforms and its coactivators transcript and protein levels were analyzed. We found significant change in transcript levels of the some of the molecules tested. While the endogenous protein levels of various AP-2 isoforms were undetectable, we found stabilization of AP-2α protein expressed from exogenous
source in cells treated with HDIs. HDI stabilized AP-2α was found to be functionally active as it showed increased sequence-specific DNA-binding as well as increased apoptosis. While HDIs known for their ability to modulate the gene activities by chromatin remodeling, it is also known that they alter various signal transduction pathways. In an effort to find pathway(s) by which HDIs activate AP-2 activity, we found that HDIs failed to activate AP-2 reporter in the presence of staurosporine suggesting the involvement a staurosporine sensitive pathway(s) in
this process. Stauosporine is a non-specific kinase inhibitor of different signaling pathways.
Further studies using different pathway specific inhibitors identified that spleen tyrosine kinase (Syk) is essential for HDIs mediated activation of AP-2 activity. Syk is a non receptor tyrosine kinase which is known to be activated in stress conditions. Syk is considered to be a tumor suppressor since Syk over expression leads to growth suppression of breast cancer cells and is
also inactivated in a subset of breast cancers. These results suggest that HDI mediated activation of AP-2 involves AP-2α stabilization through Syk pathway.
Regulation of AP-2 by MAP kinase pathway
Cell growth, differentiation, and apoptosis are mediated by the activation of mitogenactivated protein kinase (MAPK) pathways. These kinases constitute MAP kinase cascades mainly regulated through phosphorylation status. In mammalian cells, at least four MAPKs, namely, extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinase/stress-activated
protein kinases (JNK/SAPKs), p38 and ERK5/big MAP kinase have been identified. The ERKs are usually activated by mitogenic stimuli which in turn increase the proliferation and survival.
Over expression of any activator of this signaling cascade lead to the unregulated proliferation of cells. In many cancers, ERK pathways are known to be up regulated. In this study, we found that MEK (MEK is the immediate upstream regulator of ERK) inhibitors - PD98059 and U0126 activate 3X-AP2-CAT suggesting that AP-2 activity is repressed by activated MAP kinase pathway. MEK inhibitor mediated activation was found to be specific because they failed to
activate transcription from pGL tk Luc which contains thymidine kinase minimal promoter and no AP-2 binding sites. To understand the mechanism of MEK inhibitor-mediated of AP-2
activation, AP-2 isoforms and its coactivators transcript and protein levels were analyzed. We found significant change in transcript levels of the some of the molecules tested. The endogenous protein levels of various AP-2 isoforms were undetectable. When AP-2α was exogenously expressed, while no change in protein levels and DNA-binding ability was seen, we found evidence for appearance of post-ranslationally modified AP-2α protein in U0126 treated cells. We also found CITED2 (CBP/p300-interacting transactivator 2, co-activator of AP-2α) transcript levels were up regulated in UO126 treated cells. Post translational modifications of AP-2α and increased and increased CITED2 levels may be responsible for MEK inhibitor mediated AP-2 activation. Thus we conclude that ERK pathway, which is an oncogenic MAP kinase pathway, inhibits AP-2 activity thereby suggesting the importance of down regulation of AP-2 activity during transformation.
Essential role of DNA-binding domain of AP-2α for its growth inhibitory functions
Transcription factor AP-2α has three distinct domains, N-terminal transactivation
domain (52-108 aa), C-terminal DNA binding domain (204-408 aa) and dimerization domain
(277-395 aa) which lies within the DNA binding domain. AP-2α exerts its effects through binding to specific DNA sequence in the promoter of its target genes leading to either repression or activation. Recent evidences suggest that AP-2α represses many genes through its competitive binding to overlapping AP-2 and other transcription factor binding sites. This suggests an important role exclusively for the DNA binding domain in AP-2α mediated functions. To address the importance of DNA binding domain for AP-2α mediated apoptosis,
we have tested the ability different deletion/point mutants of AP-2α with varying DNA binding and transactivation capability to perform growth suppressor function and ability to induce apoptosis. Replication-deficient recombinant adenoviruses expressing different mutants were used in this study. We found that an intact DNA-binding domain alone even in the absence of
activation domain is sufficient for AP-2α to inhibit colony formation and to induce significant levels of apoptosis. These results suggest an important role for DNA binding domain growth inhibitory functions of AP-2α and thereby implying the importance of transcriptional repression in AP-2α functions.
|
27 |
Preclinical Efficacy and Safety Evaluation of Novel Small-Molecule Targeted Agents for the Prevention and Treatment of Prostate CancerSargeant, Aaron Matthew 02 September 2009 (has links)
No description available.
|
Page generated in 0.057 seconds